Bioinformatic analyses using the gene expression signature of panels of top biomarkers for low mood/depression (Table 4) identified new potential therapeutics for depression, such as the beta-blocker and serotonin 5HT1A presynaptic receptor antagonist pindolol, the PPAR-alpha activator and lipid lowering agent ciprofibrate, the PPAR-γ activator and anti-diabetic pioglitazone, and the anticholinergic and antispasmodic adiphenine. This evidence concerns the gene PPARG and depressive symptom measurement.